Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03750188 · ClinicalTrials.gov registry record

Evaluation of Safety and Efficacy of ProHance in Pediatric Patients <2yrs

A clinical trial, sponsored by Bracco Diagnostics.

Completed
Registry status
125
Enrollment target

NCT03750188 is a clinical trial that has completed, run by Bracco Diagnostics. The registered enrollment target is 125 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03750188 has completed, sponsored by Bracco Diagnostics.

COMPLETED
Registry status
125 participants
Enrollment target

Study Summary

Safety and Efficacy Study in pediatric subjects \<2 years of age who have undergone Brain or Spine MRI pre and post 0.1 mmol/kg ProHance administration. Imaging conditions will represent those in routine clinical practice. Retrospective enrolment with a prospective blinded read.

Interventions

  • DRUG ProHance

Trial Details

FieldValue
Enrollment Target 125 participants
Start Date 2018-11-01
Est. Completion 2019-10-16

Sponsor

Bracco Diagnostics

37 total trials

What the Registry Record Tells You About NCT03750188

The ClinicalTrials.gov registry entry for NCT03750188 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 125 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bracco Diagnostics, which has 37 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which ProHance is the first listed.

NCT03750188 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03750188 about?

NCT03750188 is a clinical study titled "Evaluation of Safety and Efficacy of ProHance in Pediatric Patients <2yrs". Safety and Efficacy Study in pediatric subjects \<2 years of age who have undergone Brain or Spine MRI pre and post 0.1 mmol/kg ProHance administration. Imaging conditions will represent those in routine clinical practice. Retrospective enrolment with a prospective blinded read.

What is the current status of trial NCT03750188?

This trial is currently completed. The enrollment target is 125 participants. The study started on 2018-11-01. Estimated completion is 2019-10-16.

What interventions are being tested in trial NCT03750188?

The interventions under investigation include: ProHance (DRUG).

Who is sponsoring clinical trial NCT03750188?

This trial is sponsored by Bracco Diagnostics, which has 37 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.